Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study was conducted to investigate the potential for a pharmacokinetic drug-drug
interaction in support of the co-administration of LCZ696 and sildenafil.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Sildenafil Citrate